Media centre

Want to know the latest about Vernalis? You’ve come to the right place. The media centre is where you can find the most up to date information about Vernalis, our commercial products, the drug candidates in our pipeline, our financial activities, our board of directors, and more.

  • Two approved products for the US pharmaceutical market
  • Broad and maturing cough cold pipeline
  • NCE portfolio of partnered programmes
  • Expertise in structure-based and fragment-based drug discovery
  • Strong financial position, dedicated leadership team

 

What has Vernalis been saying?

All our press releases, for you to browse and read

Lastest releases

Want to know the latest?

From the London Stock Exchange’s regulatory news service

Regulatory announcements

Vernalis makes regular public presentations

Check out the latest presentations for yourself

Presentations and Webcasts

Need to talk to someone?

These are the contact details to use

Media contacts

 
 

Latest News

FDA Issues a Complete Response Letter on CCP-08 NDA

Vernalis plc announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-08. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch